专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09282195B2 Echo canceller and echo cancellation method 有权
标题翻译：回波消除器和回波消除方法
公开(公告)号：US09282195B2
公开(公告)日：2016-03-08
申请号：US14368953
申请日：2012-03-15
申请人： Tao Xue , Tao Sun , Dongmei Liu , Jinjun Wang , Qi Zhang , Xia Wang
发明人： Tao Xue , Tao Sun , Dongmei Liu , Jinjun Wang , Qi Zhang , Xia Wang
IPC分类号： H04M1/00 , H04M9/08 , G10K11/16
CPC分类号： H04M9/082 , G10K11/16
摘要： An echo canceller and an echo cancellation method are provided. The echo canceller includes a self-adaptive filter, a voice signal detection portion and a path change detection portion; a far-end voice signal is propagated in an echo path through a speaker and is picked up by a microphone to form an echo signal. The self-adaptive filter is configured to receive the far-end voice signal as a training signal to simulate the echo path, and cancel the echo signal in a near-end signal. The voice signal detection portion is configured to detect a communication status, control the self-adaptive filter according to the communication status, and control startup of the path change detection portion according to the communication status. The path change detection portion is configured to detect whether a change occurs on the echo path, and control the self-adaptive filter according to whether the change occurs on the echo path.
摘要翻译：提供回声消除器和回声消除方法。回波消除器包括自适应滤波器，语音信号检测部分和路径变化检测部分; 远端语音信号通过扬声器在回波路径中传播，并由麦克风拾取以形成回波信号。自适应滤波器被配置为接收远端语音信号作为训练信号以模拟回波路径，并且消除近端信号中的回波信号。语音信号检测部被配置为检测通信状态，根据通信状态来控制自适应滤波器，并且根据通信状态来控制路径变化检测部的启动。路径变化检测部被配置为检测在回波路径上是否发生变化，并且根据在回波路径上是否发生变化来控制自适应滤波器。

2. 发明申请

US20140329568A1 ECHO CANCELLER AND ECHO CANCELLATION METHOD 有权
标题翻译： ECHO CANCELLER和ECHO CANCELLATION方法
公开(公告)号：US20140329568A1
公开(公告)日：2014-11-06
申请号：US14368953
申请日：2012-03-15
申请人： Tao Xue , Tao Sun , Dongmei Liu , Jinjun Wang , Qi Zhang , Xia Wang
发明人： Tao Xue , Tao Sun , Dongmei Liu , Jinjun Wang , Qi Zhang , Xia Wang
IPC分类号： H04M9/08 , G10K11/16
CPC分类号： H04M9/082 , G10K11/16
摘要： An echo canceller and an echo cancellation method are provided. The echo canceller includes a self-adaptive filter, a voice signal detection portion and a path change detection portion; a far-end voice signal is propagated in an echo path through a speaker and is picked up by a microphone to form an echo signal. The self-adaptive filter is configured to receive the far-end voice signal as a training signal to simulate the echo path, and cancel the echo signal in a near-end signal. The voice signal detection portion is configured to detect a communication status, control the self-adaptive filter according to the communication status, and control startup of the path change detection portion according to the communication status. The path change detection portion is configured to detect whether a change occurs on the echo path, and control the self-adaptive filter according to whether the change occurs on the echo path.
摘要翻译：提供回声消除器和回声消除方法。回波消除器包括自适应滤波器，语音信号检测部分和路径变化检测部分; 远端语音信号通过扬声器在回波路径中传播，并由麦克风拾取以形成回波信号。自适应滤波器被配置为接收远端语音信号作为训练信号以模拟回波路径，并且消除近端信号中的回波信号。语音信号检测部被配置为检测通信状态，根据通信状态来控制自适应滤波器，并且根据通信状态来控制路径变化检测部的启动。路径变化检测部被配置为检测在回波路径上是否发生变化，并且根据在回波路径上是否发生变化来控制自适应滤波器。

3. 发明授权

US07745437B2 Compounds and compositions as protein kinase inhibitors 有权
标题翻译：化合物和组合物作为蛋白激酶抑制剂
公开(公告)号：US07745437B2
公开(公告)日：2010-06-29
申请号：US11628881
申请日：2005-06-09
申请人： Pingda Ren , Xia Wang , Guobao Zhang , Qiang Ding , Shuli You , Qiong Zhang , Greg Chopiuk , Pamela A. Albaugh , Taebo Sim , Nathanael Schiander Gray
发明人： Pingda Ren , Xia Wang , Guobao Zhang , Qiang Ding , Shuli You , Qiong Zhang , Greg Chopiuk , Pamela A. Albaugh , Taebo Sim , Nathanael Schiander Gray
IPC分类号： C07D403/04 , A61K31/4178
CPC分类号： C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ΣΓK, Tιε2, Λχκ, θNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症，PDGF-R，trkB，c-SRC，BMX，FGFR3，b-RAF，＆amp; Ggr; K，Tι＆egr; 2，Λχ＆kgr;; thetas;NK2α2，MKK4，c-RAF，MKK6，SAPK2α和SAPK2＆激酶。

4. 发明申请

US20090105250A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS 审中-公开
标题翻译：作为蛋白激酶抑制剂的化合物和组合物
公开(公告)号：US20090105250A1
公开(公告)日：2009-04-23
申请号：US11814912
申请日：2006-01-19
申请人： Taebo Sim , Nathanael Schiander Gray , Hyun Soo Lee , Yi Liu , Pingda Ren , Shuli You , Qiong Zhang , Qiang Ding , Xia Wang , Songchun Jiang , Pamela A. Albaugh
发明人： Taebo Sim , Nathanael Schiander Gray , Hyun Soo Lee , Yi Liu , Pingda Ren , Shuli You , Qiong Zhang , Qiang Ding , Xia Wang , Songchun Jiang , Pamela A. Albaugh
IPC分类号： A61K31/427 , C07D277/56 , C07D417/14 , C07D417/12 , A61K31/454 , A61K31/506 , A61K31/5377 , A61K31/426
CPC分类号： C07D277/56 , C07D417/12 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, FGFR3, PDGFRβ and b-Raf kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，Bcr-Abl异常活化的疾病或病症，FGFR3，PDGFRbeta和b-Raf激酶。

5. 发明申请

US20090076064A1 Compounds 审中-公开
标题翻译：化合物
公开(公告)号：US20090076064A1
公开(公告)日：2009-03-19
申请号：US12159993
申请日：2007-01-03
申请人： Rebecca Urbanek , Dean Brown , Gary Steelman , William Blackwell , Steven Wesolowski , Xia Wang
发明人： Rebecca Urbanek , Dean Brown , Gary Steelman , William Blackwell , Steven Wesolowski , Xia Wang
IPC分类号： A61K31/439 , C07D471/08 , C07D401/12 , A61K31/4545
CPC分类号： C07D405/12 , C07D401/12 , C07D413/12 , C07D451/06
摘要： Disclosed are compounds of Formula (I) wherein G, R2, A, D and E are as described in the specification, or pharmaceutically-acceptable salts, or in vivo-hydrolysable precursors thereof. Also disclosed herein is at least one method of making, at least one pharmaceutical composition containing, and at least one method for using at least one compound in accordance with Formula I.
摘要翻译：公开了式（I）的化合物，其中G，R 2，A，D和E如说明书中所述，或其药学上可接受的盐或其体内可水解的前体。本文还公开了至少一种制备至少一种药物组合物的方法，所述至少一种药物组合物含有和至少一种使用至少一种根据式I的化合物的方法。

6. 发明申请

US20080221098A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS 失效
标题翻译：作为蛋白激酶抑制剂的化合物和组合物
公开(公告)号：US20080221098A1
公开(公告)日：2008-09-11
申请号：US12099708
申请日：2008-04-08
申请人： Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Schiander Gray , Shuli You
发明人： Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Schiander Gray , Shuli You
IPC分类号： A61K31/5377 , C07D487/04 , A61K31/519 , A61K31/496
CPC分类号： C07D487/04 , C07D471/04
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症，Bmx，c-Raf，Csk，Fes，FGFR，Flt3，Ikk，IR，JNK，Lck，Mkk，PKC，PKD，Rsk，SAPK，Syk，Trk，BTK，Src，EGFR，IGF，Mek，Ros和Tie2 激酶。

7. 发明申请

US20080188483A1 Compounds and Compositions as Protein Kinase Inhibitors 审中-公开
标题翻译：化合物和组合物作为蛋白激酶抑制剂
公开(公告)号：US20080188483A1
公开(公告)日：2008-08-07
申请号：US11817951
申请日：2006-03-10
申请人： Pingda Ren , Nathanael Schiander Gray , Xia Wang , Guobao Zhang
发明人： Pingda Ren , Nathanael Schiander Gray , Xia Wang , Guobao Zhang
IPC分类号： A61K31/496 , C07D487/04 , A61K31/519
CPC分类号： C07D487/04 , A61K31/519 , A61K31/52
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRβ, PKA, PKBβ, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，Bcr-Abl异常活化的疾病或病症，BMX，BTK，CHK2，c-RAF，CSK，c-SRC，Fes，FGFR3，Flt3，IKKalpha，IKKbeta，JNK2alpha2，Lck，Met，MKK4，MKK6，MST2，NEK2，p70S6K，PDGFRbeta，PKA，PKBbeta，PKD2 ，Rsk1，SAPK2alpha，SAPK2beta，SAPK3，SGK，Tie2和TrkB激酶。

8. 发明授权

US07371750B2 Compounds and compositions as protein kinase inhibitors 失效
标题翻译：化合物和组合物作为蛋白激酶抑制剂
公开(公告)号：US07371750B2
公开(公告)日：2008-05-13
申请号：US10909227
申请日：2004-07-29
申请人： Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Guobao Zhang , Yi Liu , Xia Wang , Tetsuo Uno , Bing Li , Lintong Li , Nathanael Schiander Gray , Shuli You
发明人： Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Guobao Zhang , Yi Liu , Xia Wang , Tetsuo Uno , Bing Li , Lintong Li , Nathanael Schiander Gray , Shuli You
IPC分类号： A61K31/5355 , A61K31/53 , A61K31/497 , A61K31/513 , C07D413/12 , C07D253/065 , C07D487/04 , C07D413/14 , A61P35/00 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症，Bmx，c-Raf，Csk，Fes，FGFR，Flt3，Ikk，IR，JNK，Lck，Mkk，PKC，PKD，Rsk，SAPK，Syk，Trk，BTK，Src，EGFR，IGF，Mek，Ros和Tie2 激酶。

9. 发明申请

US20050222177A1 Compounds and compositions as protein kinase inhibitors 失效
标题翻译：化合物和组合物作为蛋白激酶抑制剂
公开(公告)号：US20050222177A1
公开(公告)日：2005-10-06
申请号：US10909227
申请日：2004-07-29
申请人： Taebo Sim , Hyun Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Gray , Shuli You
发明人： Taebo Sim , Hyun Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Gray , Shuli You
IPC分类号： A61K20060101 , A61K31/5025 , A61K31/519 , C07D471/04 , C07D487/02 , C07D487/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症，Bmx，c-Raf，Csk，Fes，FGFR，Flt3，Ikk，IR，JNK，Lck，Mkk，PKC，PKD，Rsk，SAPK，Syk，Trk，BTK，Src，EGFR，IGF，Mek，Ros和Tie2 激酶。

10. 发明申请

US20130198397A1 Method and Apparatus for Performing Multiple Forms of Communications in One Session 有权
标题翻译：在一个会话中执行多种通信形式的方法和装置
公开(公告)号：US20130198397A1
公开(公告)日：2013-08-01
申请号：US13519649
申请日：2009-12-31
申请人： Guohua Zhang , Jilei Tian , Xia Wang , Wei Wang , Feng Ding , Yuezhong Tang , Xinxing Yang , Ari Aarnio
发明人： Guohua Zhang , Jilei Tian , Xia Wang , Wei Wang , Feng Ding , Yuezhong Tang , Xinxing Yang , Ari Aarnio
IPC分类号： H04L29/06
CPC分类号： H04L65/1066 , G10L13/00 , G10L15/26 , G10L25/48 , H04L65/1089 , H04L65/4007 , H04W4/02 , H04W4/18 , H04W4/50
摘要： An approach is provided for performing multiple and hybrid forms of communication in the same communication session. A communication manager receives a to establish a communication session using a first form of communication, wherein the communication session supports multiple and simultaneous forms of communication. Next, the communication manager selects a second form of communication to conduct the communication session. Then, the communication manager transcodes the second form of communication to the first form of communication. The different forms can be converted to facilitate and enrich the communication capability, according to an embodiment of the invention.
摘要翻译：提供了一种用于在相同通信会话中执行多种和混合形式的通信的方法。通信管理器接收用于使用第一通信形式建立通信会话，其中通信会话支持多种并且同时形式的通信。接下来，通信管理器选择第二形式的通信以进行通信会话。然后，通信管理器将第二形式的通信转码为第一通信形式。根据本发明的实施例，可以转换不同的形式以促进和丰富通信能力。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式